Statins prove effective for primary prevention in low-risk patients with Type 2 diabetes, challenging conventional guidelines. A recent study challenges the notion that statins are only beneficial for high-risk patients with Type 2 diabetes. The research, published in the Annals of Internal Medicine, suggests that statins offer significant long-term benefits even for low-risk individuals, particularly those with elevated LDL cholesterol levels.
The study, led by Vincent Ka Chun Yan, PhD, and Joseph Edgar Blais, PhD, both from the University of Hong Kong, analyzed data from the IQVIA Medical Research Data resource in the United Kingdom. They examined the outcomes associated with statin use in patients across various risk levels, including those with Type 2 diabetes diagnosed between 2005 and 2016 and no prior history of statin use, coronary artery disease, or other specified conditions.
The researchers divided patients into four groups based on their predicted 10-year cardiovascular disease (CVD) risk using the QRISK3 tool: low (< 10%), intermediate (10% to 19%), high (20% to 29%), and very high (≥ 30%). After propensity-score matching, the analysis included a substantial number of eligible person-trials for each risk group.
The findings revealed that statin use was associated with reduced risks of all-cause mortality and major CVD events across all risk strata. Interestingly, the benefits were most pronounced in low-risk patients with elevated LDL cholesterol levels, challenging the notion that statins are only for high-risk individuals.
The study also found that statin use was not associated with significant differences in myopathy or liver dysfunction, addressing safety concerns. However, the researchers noted that long-term adherence to statins is crucial for realizing the full benefits, as the advantages become more apparent over several years.
The study's findings have significant implications for clinical practice, suggesting that statins should be considered for most adults with Type 2 diabetes, not just those at high risk. This inclusive approach may help harmonize international guidelines and promote individualized decision-making regarding statin therapy.
